{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:50:59Z","timestamp":1791899459446,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bone.2020.115553","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T13:51:28Z","timestamp":1595857888000},"page":"115553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["The role of endogenous GIP and GLP-1 in postprandial bone homeostasis"],"prefix":"10.1016","volume":"140","author":[{"given":"Mads M.","family":"Helsted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e6rke S.","family":"Gasbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie R.","family":"Lanng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha C.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Stensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolette","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel B.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette M.","family":"Rosenkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115553_bb0005","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology."},{"key":"10.1016\/j.bone.2020.115553_bb0010","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia."},{"key":"10.1016\/j.bone.2020.115553_bb0015","doi-asserted-by":"crossref","DOI":"10.2337\/db17-0480","article-title":"The gluco- and liporegulatory and the vasodilatory effects of glucose-dependent insulinotropic polypeptide (GIP) are abolished by an antagonist of the human GIP receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes."},{"key":"10.1016\/j.bone.2020.115553_bb0020","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes."},{"key":"10.1016\/j.bone.2020.115553_bb0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1210\/jc.2017-01949","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) inhibits bone resorption independently of insulin and glycemia","volume":"103","author":"Christensen","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115553_bb0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1055\/s-2004-826158","article-title":"On the physiology of GIP and GLP-1","volume":"36","author":"Holst","year":"2004","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.bone.2020.115553_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S8756-3282(01)00662-7","article-title":"Mechanism of circadian variation in bone resorption","volume":"30","author":"Bjarnason","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115553_bb0040","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1210\/jc.2002-021447","article-title":"Octreotide abolishes the acute decrease in bone turnover in response to oral glucose","volume":"88","author":"Clowes","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115553_bb0045","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.bone.2005.06.021","article-title":"Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover","volume":"37","author":"Xie","year":"2005","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115553_bb0050","doi-asserted-by":"crossref","first-page":"E2325","DOI":"10.1210\/jc.2014-2547","article-title":"Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans","volume":"99","author":"Nissen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115553_bb0055","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.141.3.7366","article-title":"Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors 1","volume":"141","author":"Bollag","year":"2000","journal-title":"Endocrinology."},{"key":"10.1016\/j.bone.2020.115553_bb0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.071202","article-title":"Impact of glucose-dependent insulinotropic peptide on age-induced bone loss","volume":"23","author":"Ding","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115553_bb0065","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bone.2020.115553_bb0070","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1359\/jbmr.2003.18.12.2180","article-title":"Role of gastrointestinal hormones in postprandial reduction of bone resorption","volume":"18","author":"Henriksen","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115553_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115553_bb0080","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1210\/jc.2015-1176","article-title":"GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women","volume":"100","author":"Iepsen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115553_bb0085","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bph.13384","article-title":"N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor","volume":"173","author":"Hansen","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bone.2020.115553_bb0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00125-017-4447-4","article-title":"GIP(3\u221230)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study","volume":"61","author":"Gasbjerg","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.bone.2020.115553_bb0095","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined gluco-metabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes."},{"key":"10.1016\/j.bone.2020.115553_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgz175","article-title":"GIP and GLP-1 receptor antagonism during a meal in healthy individuals","volume":"105","author":"Gasbjerg","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115553_bb0105","series-title":"Exendin (9\u201339) amide Is an Antagonist of Glucagon-like Peptide-1 (7\u201336) amide in Humans","first-page":"1421","volume":"101","author":"Schirra","year":"1998"},{"key":"10.1016\/j.bone.2020.115553_bb0110","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2337\/diabetes.48.1.86","article-title":"Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39","volume":"48","author":"Edwards","year":"1999","journal-title":"Diabetes."},{"key":"10.1016\/j.bone.2020.115553_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcp.2018.01.040","article-title":"Human GIP(3-30)NH2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors","volume":"150","author":"Gabe","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bone.2020.115553_bb0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bone.2019.05.014","article-title":"GLP-2 and GIP exert separate effects on bone turnover: a randomized, placebo-controlled, crossover study in healthy young men","volume":"125","author":"Skov-Jeppesen","year":"2019","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115553_bb0125","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00198-017-4026-z","article-title":"Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population","volume":"28","author":"J\u00f8rgensen","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115553_bb0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EC-15-0022","article-title":"The effects of acute hyperinsulinemia on bone metabolism","volume":"4","author":"Ivaska","year":"2015","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.bone.2020.115553_bb0135","series-title":"Diabetologia","first-page":"S234","article-title":"[Abstract] Gut hormones, rather than glucose or insulin, are the main drivers of diminished bone resorption in the postabsorptive state","author":"Lund","year":"2016"},{"key":"10.1016\/j.bone.2020.115553_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.93936","article-title":"Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes","volume":"3","author":"Bahne","year":"2018","journal-title":"JCI Insight."},{"key":"10.1016\/j.bone.2020.115553_bb0145","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1172\/JCI1349","article-title":"Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans","volume":"101","author":"Schirra","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2020.115553_bb0150","series-title":"The Efficacy of Exendin(9\u201339)Amide as a GLP-1 Receptor Antagonist in Human","author":"Schirra","year":"2008"},{"key":"10.1016\/j.bone.2020.115553_bb0155","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2019-00008","article-title":"Separate and combined effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes","author":"Bergmann","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115553_bb0160","series-title":"Diabetes","first-page":"A305","article-title":"[Abstract] Liraglutide-induced weight loss does not compromise bone mineral density or markers of bone turnover in overweight patients with type 1 diabetes","author":"Dejgaard","year":"2017"},{"key":"10.1016\/j.bone.2020.115553_bb0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.morpho.2016.06.004","article-title":"Interplay between bone and incretin hormones: a review","volume":"101","author":"Mabilleau","year":"2017","journal-title":"Morphologie."},{"key":"10.1016\/j.bone.2020.115553_bb0170","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1210\/me.2005-0187","article-title":"Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after","volume":"20","author":"Tsukiyama","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.bone.2020.115553_bb0175","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bone.2016.07.014","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) dose-dependently reduces osteoclast differentiation and resorption","volume":"91","author":"Mabilleau","year":"2016","journal-title":"Bone."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220303331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220303331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:48:48Z","timestamp":1757612928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220303331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":35,"alternative-id":["S8756328220303331"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115553","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of endogenous GIP and GLP-1 in postprandial bone homeostasis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115553"}}